These results suggest that targeting OXPHOS is potentially effective in the treatment of CRCs and other types of cancers that are capable of glycolysis, with the inhibition of GOT1 as a potential approach to sensitize CRC cells to OXPHOS-targeting therapies. The gene discussed is GOT1; the disease is cancer.